Designated as NDV-Inact-VG-API, the product is an inactivated Newcastle disease virus antigen concentrate prepared from specific-pathogen-free embryonated chicken eggs. Model variants comprise strain-specific and presentation-specific grades: NDV-Inact-VG-API/LaSota lyophilized, NDV-Inact-VG-API/LaSota liquid, NDV-Inact-VG-API/Ulster 2C lyophilized, and NDV-Inact-VG-API/VG/GA frozen. The default inactivation chemistry is binary ethylenimine at 10 mM for 24 h at 26 °C, followed by neutralization with sodium thiosulfate. The resulting antigen concentrate is clarified by continuous-flow centrifugation, diafiltered against phosphate-buffered saline at pH 7.2, and filtered to a low-bioburden or sterile state depending on the intended downstream formulation. The product is an unadjuvanted veterinary active pharmaceutical ingredient for further manufacture into tablets, injections, capsules, powders, granules, premixes, and solutions; it is not a finished biological product.

Release of the inactivated antigen concentrate requires control of kill, antigen identity, sterility, endotoxin, residual moisture, and potency. Because the virus is non-replicating, the critical quality attributes shift from infectivity to structural integrity of the haemagglutinin-neuraminidase and fusion glycoproteins. Potency is verified in accordance with 9 CFR 113.205 for killed Newcastle disease vaccine, with additional antigen quantification by ELISA or haemagglutination assay linked to a reference preparation. The acceptance criterion for antigen content is expressed as a log2 haemagglutination titre or relative potency units per milligram of lyophilized solids. Foreign-protein content from egg-derived allantoic fluid is controlled because it can interfere with inactivation kinetics and downstream tableting stability.

Production-scale lyophilization of the antigen premix uses a shelf freeze-dryer with product loading matched to the batch size. A typical cycle cools the filled trays to -40 °C at 0.5 °C/min, holds for 4 h, then initiates primary drying at -20 °C and chamber pressure 0.1 mbar for 36 h. Secondary drying is performed at 20 °C for 6 h to reduce residual moisture below 3.0%. Batch-to-batch variance in cake resistance can shift primary drying time by ±8 h; therefore, product temperature is monitored with thermocouples and the cycle is not advanced strictly by time. Collapse of the lyophilized cake is a known failure mode when the product temperature exceeds the collapse temperature, which for this type of antigen matrix is measured in the range of -25 °C to -18 °C.

What differentiates a killed Newcastle disease virus antigen concentrate from live attenuated seed material?

The product is non-replicating, so it does not produce post-vaccination mucosal shedding or revert to virulence. Live attenuated NDV vaccines based on VG/GA or LaSota require intact cold-chain maintenance and may be contraindicated in certain poultry compartments, whereas the inactivated antigen API can be incorporated into adjuvanted parenteral formulations where the immune response depends on retained glycoprotein structure rather than replication in the host. This distinction shifts release testing from virus titre in egg infective dose to antigen mass and potency in challenge or serological models. The absence of live virus also lowers biocontainment requirements during tablet and premix handling, but it introduces a need for potency verification after each unit operation.

Inactivation validation uses duplicate passages in SPF embryonated chicken eggs according to 9 CFR 113.205, with allantoic fluid harvested at 72 h and 120 h post-inoculation and no haemagglutination activity permitted. Kinetic sampling at 0 h, 2 h, 4 h, 8 h, 16 h, and 24 h demonstrates a biphasic decline. The second log-reduction phase can be influenced by protein load in allantoic fluid, so batch-to-batch variance in egg-derived protein is controlled below 1.5 mg/mL before inactivation to avoid tailing. A process deviation exceeding 0.5 pH units from the inactivation target or a temperature drift above 28 °C triggers revalidation of the kill kinetics.

Representative release expectations may vary with the competent-authority approval, virus strain, and downstream product. The limits in the table are not a substitute for batch-specific release testing under the applicable marketing authorization.

Strain selection alters the antigenic breadth and downstream potency. The LaSota variant generally provides broad protection and high yield in embryonated eggs, while Ulster 2C is used where lower respiratory reactivity is desired. The VG/GA variant is relevant in certain markets where local NDV field strains are genetically aligned. The model code identifies the strain and physical presentation, and the certificate of analysis reports the corresponding haemagglutination titre, protein content, and residual inactivating agent.

Unlike adjuvanted finished Newcastle disease vaccines, this API does not contain preservatives or adjuvants. The absence of mineral oil and surfactants permits its use in dry solid-dose forms, whereas finished oil-emulsion vaccines cannot be converted into tablets or dry feed premixes. Some inactivated NDV antigen products are supplied as oil-emulsion components or frozen allantoic fluid; this grade uses a lyophilization-compatible stabilizer matrix with a residual moisture specification and no mineral oil in the certificate of analysis.

When freeze-dried Newcastle disease antigen enters tablet compression, pressure and humidity control the titre recovery

Direct-compression tablet manufacture of the antigen premix requires balancing the mechanical strength of the tablet with the thermal and pressure sensitivity of the inactivated virus antigen. The lyophilized powder is blended with mannitol, microcrystalline cellulose, and trehalose in a twin-shell blender at 15 rpm for 20 min, then lubricated with magnesium stearate at 0.5% w/w. A rotary tablet press with precompression is configured to a main compression force in the range of 50–110 MPa. Published data for this specific configuration is limited; therefore, process capability studies should bracket compression force and monitor haemagglutination titre loss at each station. The glass transition temperature of the trehalose-based stabilizer matrix is approximately 115 °C, and the press cycle should keep the punch temperature below 35 °C to avoid localised collapse of the lyophilized cake structure.

Fluid-bed granulation is used for granules and encapsulated powders. A top-spray configuration with inlet air temperature below 35 °C and product temperature at 25–30 °C reduces antigen denaturation. The atomization air pressure is set at 1.5–2.0 bar, and the spray rate is adjusted to maintain final granule moisture at ≤5.0%. After drying, the granules are milled through a 1.0 mm screen and blended. Segregation in the final powder blend is evaluated by sampling at 10 locations; acceptance is based on relative standard deviation of antigen content below 5.0%.

Tablets and capsules are not the primary parenteral route for inactivated Newcastle disease vaccine; oral and mucosal solid dosage forms require enteric protection because Newcastle disease virus haemagglutinin is acid-labile. Enteric coating with a methacrylic acid copolymer to a weight gain of 8–10% is typical when release in the upper small intestine is desired. Dissolution testing according to USP <711> is used to confirm release at pH 6.8 after an acid-stage exposure at pH 1.2 for 2 h. If the coating is cracked, antigen potency loss is rapid; visual inspection and disintegration testing at 37 °C are therefore included as in-process controls.

Capsule filling is performed with dosator-type equipment at room temperature and relative humidity below 40% RH. Gelatin capsule shells are less suitable than hydroxypropyl methylcellulose when the filled powder moisture exceeds 3.0% because shell embrittlement occurs. The capsule formulation uses the same direct-compression filler-binder system as tablets, but the absence of compression force eliminates the punch-temperature risk; the remaining critical variable is moisture uptake during storage.

Observed failure modes on rotary tablet presses include sticking to punch faces when residual moisture exceeds 3.0% and capping when compression force exceeds 120 MPa in trehalose-based matrices. Precompression force is set at 10–20% of main compression force to expel air and reduce capping. Tablet hardness is tested per USP <1217>; a target hardness of 60–100 N is common for direct-compression veterinary tablets. Over-mixing in the blender can generate shear-induced protein aggregation; fill volume is therefore maintained at 50–70% of vessel capacity.

Premix and solution integration limits in feed and liquid dosage systems

Powder and granule presentations are prepared by adsorption of the diafiltered antigen onto maltodextrin, lactose, or calcium carbonate carriers. The carrier is selected to avoid reducing sugars that can drive Maillard degradation of the viral glycoproteins. Feed premix stability is evaluated at 25 °C and 60% RH with periodic haemagglutination titre and ELISA antigen recovery. Published data for this specific configuration is limited, so the stability of each new carrier lot should be established by a bracketed study rather than assumed from small-molecule vitamin premix data. Ribbon mixers used for 500 kg production batches require validation of mixing time because extended mixing can generate fines and reduce particle-size uniformity. A 10-min mixing time at 25 rpm is a typical starting point; final homogeneity is confirmed by thief sampling at 10 locations with a relative standard deviation below 5.0%.

Injectable solutions are produced by reconstituting the lyophilized powder or diluting the liquid concentrate in Water for Injection at 2–8 °C. Aluminium hydroxide gel or mineral oil-surfactant adjuvants are added under rotor-stator mixing at 5,000–10,000 rpm for 5–10 min. For oil-emulsion finished product, droplet size is monitored by laser diffraction; median droplet size is controlled below 5 µm to maintain emulsion stability and syringeability. The final injectable is filled under ISO Class 7 or better controlled environment per ISO 14644-1, with terminal sterilisation not applicable because heat or irradiation would destroy antigen structure. Sterile filtration of the antigen concentrate before adjuvant addition is therefore the critical sterility control for injectable solutions, and aseptic processing controls follow 21 CFR 211.113 and current good manufacturing practice.

In feed and water applications, the inactivated antigen must be protected from organic acids, chlorine, and metal-ion-mediated oxidation. Chlorinated drinking water at free chlorine levels above 1.0 ppm reduces antigen recovery after 4 h; therefore, stabilizers such as sodium thiosulfate at 0.1% w/v are added when the solution is used for oral vaccination under veterinary authorization. Avoid combination with amine-based additives that can alter pH above 7.8 and promote antigen aggregation. The product is not intended for parenteral administration unless reconstituted and adjuvanted under controlled pharmaceutical conditions.